This paper examines automated Business Continuity Planning (BCP) for biopharmaceutical companies during pandemics. It analyzes COVID-19's impact on the industry, including sales declines and supply chain disruptions. A risk analysis framework is presented, followed by a comprehensive BCP strategy based on the FEMA model. The study proposes crisis management techniques, monitoring systems, technical support integration, and safety measures. It also reviews industry policies and provides a detailed implementation plan with budget considerations. The research emphasizes the importance of adaptable crisis management, continuous monitoring, and collaborative approaches in developing effective BCPs for biopharmaceutical companies.

Chao Wu. Automated BCP for Biopharmaceutical Company under Pandemic Diseases. International Journal of Frontiers in Engineering Technology (2024), Vol. 6, Issue 4: 19-24. https://doi.org/10.25236/IJFET.2024.060404.

[1] Rezaee Z. The Sustainable Business Blueprint: Planning, Performance, Risk, Reporting, and Assurance. (2024) Taylor & Francis.

[2] IO. Introduction of business continuity plan for small and medium-sized local construction companies and restoration activities in Japan in the event of natural disasters. (2023) IOP Conference Series: Earth and Environmental Science, 1195(1).

[3] Taro K, MizukiU, Chie I, et al. Collective Knowledge and Experience for Resource-Focused Business Continuity Plans Foundation: Survey on How Home-Visit Nursing Operators in Japan Coped with the COVID-19 Pandemic. (2023) jdr, 18(2).

[4] Releases Highlights Report on Global Baby Wipes Market: COVID-19 Business Continuity Plan. (2020) Wireless News.

[5] USADATA Inc.; USADATA Provides Data-Driven Recommendations and Its Business Continuity Plan for Clients during the COVID-19 Outbreak. (2020) Medical Letter on the CDC FDA.

[6] Boralex Inc., Boralex Issues Update on its Business Continuity Plan in the Context of COVID-19. (2020) Medical Letter on the CDC FDA.